The Rs 100-crore Gland Pharma Ltd has signed an agreement with Evolvence India Life Sciences Fund, a private equity fund focused on investments in life sciences businesses in the country, for capital infusion of $30 million (Rs 120 crore). The proposed fund is to support its expansion at its manufacturing facilities and fund research and development activities. The company is also open to acquisitions in the near future. Announcing this to the media, Ravi Penmetsa, vice-chairman and MD, said that the capital infusion of $30 million would help to vertically integrate the manufacturing capabilities, fund capacity expansion and file more Abbreviated New Drug Application (ANDA). Besides, the company is bullish over exports to the regulated Markets and expects 60% of its revenue to come from these Markets in the next two years. Gland Pharma has a pre-filled syringe facility in the country. Some of the Companies’ products include heparin, enoxaparin and dalteparin, used to treat blood clots and rocuronium, atracurim, etc used in anesthesia. The company is in the process of developing generic products in the oncology and anesthetic segments. […]